Which statement best describes the difference between dutasteride and finasteride in androgenetic alopecia regarding 5-alpha-reductase inhibition and potential efficacy?

Which statement best describes the difference between dutasteride and finasteride in androgenetic alopecia regarding 5-alpha-reductase inhibition and potential efficacy?

• A. Dutasteride inhibits both type I and type II 5-alpha-reductase, offering broader suppression of DHT and potentially greater efficacy, with pregnancy avoidance essential.
• B. Finasteride inhibits both type I and II 5-alpha-reductase and provides broader suppression of DHT.
• C. Dutasteride inhibits only type II 5-alpha-reductase and is less effective than finasteride.
• D. Finasteride inhibits only type II 5-alpha-reductase and is generally more effective than dutasteride.

Answer: (A)

The difference centers on how these drugs block the enzyme that makes DHT, the form of testosterone most involved in androgenetic alopecia. There are two forms of 5-alpha-reductase: type I and type II. Finasteride mainly inhibits the type II isoform, lowering DHT but not as completely because it doesn’t block the type I enzyme. Dutasteride blocks both isoforms, giving a broader and more complete suppression of DHT. Since DHT is the key driver of hair follicle miniaturization in this condition, dual inhibition can translate into greater potential effectiveness in promoting hair regrowth or slowing hair loss for some patients. A critical safety point is that exposure of a pregnant woman to these drugs can cause birth defects in a male fetus, so pregnancy avoidance and careful handling are essential. Therefore, the statement is accurate in describing dual inhibition and the possibility of greater efficacy, and it correctly reflects the safety caution.

The difference centers on how these drugs block the enzyme that makes DHT, the form of testosterone most involved in androgenetic alopecia. There are two forms of 5-alpha-reductase: type I and type II. Finasteride mainly inhibits the type II isoform, lowering DHT but not as completely because it doesn’t block the type I enzyme. Dutasteride blocks both isoforms, giving a broader and more complete suppression of DHT. Since DHT is the key driver of hair follicle miniaturization in this condition, dual inhibition can translate into greater potential effectiveness in promoting hair regrowth or slowing hair loss for some patients. A critical safety point is that exposure of a pregnant woman to these drugs can cause birth defects in a male fetus, so pregnancy avoidance and careful handling are essential. Therefore, the statement is accurate in describing dual inhibition and the possibility of greater efficacy, and it correctly reflects the safety caution.